1. Lewis RM, Laprise J-F, Gargano JW, et al. Estimated prevalence and incidence of disease-associated human papillomavirus types among 15-to 59-year-olds in the United States. Sex Transm
Dis 2021;48(4):273–7.
2. Gargano JW, Wilkinson EJ, Unger ER, et al. Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine
introduction. J Low Genit Tract Dis 2012;16(4): 471–9.
3. Sinno AK, Saraiya M, Thompson TD, et al. Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population. Obstet Gynecol 2014;123(4):817.
4. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29(32): 4294.
5. Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6(4):204. doi:10.1016/s1470-2045(05)70086-3
6. Arafah M, Rashid S, Tulbah A, Akhtar M. Carcinomas of the Uterine Cervix: Comprehensive Review With An Update on Pathogenesis, Nomenclature of Precursor and Invasive Lesions, and
Differential Diagnostic Considerations. Adv Anat Pathol. 2021;28(3):150-170. doi:10.1097/PAP.0000000000000300
7. Richard E. Shope, E. Weston Hurst; Infectıous Papıllomatosıs Of Rabbıts: Wıth A Note On The Hıstopathology . J Exp Med 1933; 58 (5): 607–624. doi: https://doi.org/10.1084/jem.58.5.607
8. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A New Type of Papillomavirus DNA, its Presence in Genital Cancer Biopsies and in Cell Lines Derived From
Cervical Cancer. EMBO J (1984) 3 (5):1151–7. doi: 10.1002/j.1460-2075.1984.tb01944.x
9. Baumann M, von Knebel Doeberitz M. Harald zur Hausen, virologist who linked viruses to cancer (1936-2023). Nature. 2023;619(7971):693. doi:10.1038/d41586-023-02370-6
10. Yousefi Z, Aria H, Ghaedrahmati F, Bakhtiari T, et al. An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy. Front. Immunol. 2022; 12: 805695. doi:
10.3389/fimmu.2021.805695
11. Van Doorslaer et al. ICTV Virus Taxonomy Profile: Papillomaviridae, Journal of General Virology, 2018;99, 989–990.
12. Yu L, Majerciak V, Zheng Z-M. HPV16 and HPV18 Genome Structure, Expression, and Post-Transcriptional Regulation. Int. J.Mol.Sci.2022,23,4943. https:// doi.org/10.3390/ijms23094943
13. Balaji D, Kalarani I.B, Mohammed V, et al. Potential role of human papillomavirus proteins associated with the development of cancer. VirusDis. 2022;33, 322–333. https://doi.org/10.1007/
s13337-022-00786-8
14. Magalhães G. M, Vieira É. C, Garcia L. C, et al. Update on human papilloma virus-part I: epidemiology, pathogenesis, and clinical spectrum. Anais Brasileiros de Dermatologia, 2010; 96, 1-16.
15. Đukić A, Lulić L, Thomas M, et al. HPV Oncoproteins and the Ubiquitin Proteasome System: A Signature of Malignancy? Pathogens. 2020; 9(2):133. https://doi.org/10.3390/pathogens9020133
16. Ilahi N.E, Bhatti A. Impact of HPV E5 on viral life cycle via EGFR signaling. Microb. Pathog. 2020;139, 103923.
17. Jain M, Yadav D, Jarouliya U. Epidemiology, Molecular Pathogenesis, Immuno-Pathogenesis, Immune Escape Mechanisms and Vaccine Evaluation for HPV-Associated Carcinogenesis. Pat-
hogens. 2023;23;12(12):1380. doi: 10.3390/pathogens12121380.
18. Kombe Kombe AJ, Li B, Zahid A, et al. Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. Front Public Health.
2021;8:552028. doi:10.3389/fpubh.2020.552028
19. Bruni, L.; Albero, G.; Serrano, B.; Mena, M.; Collado, J.; Gómez, D.; Muñoz, J.; Bosch, F.; de Sanjosé, S. Human Papillomavirus and Related Diseases in the World. Summary Report 22 October
2021; ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre): Barcelona, Spain, 2023.
20. Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020 Nov 15;17(4):864-878. doi: 10.20892/j.issn.2095-3941.2020.0370. Epub 2020 Dec 15.
PMID: 33299640; PMCID: PMC7721094.
21. Colpani V, Soares Falcetta F, Bacelo Bidinotto A, et al. Prevalence of human papillomavirus (HPV) in Brazil: A systematic review and meta-analysis. PLoS ONE 2020;15(2): e0229154. https://
doi.org/10.1371/journal.pone.0229154
22. World Health Organization Cervical Cancer. 2022. [(accessed on 27 January 2024)]. Available online: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer,
23. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer. J. Clin. 2021;71:209–
249. doi: 10.3322/caac.21660.
24. Di Donato V, Caruso G, Petrillo M, et al. Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis. Vaccines (Basel). 2021 Apr 21;9(5):410.
doi: 10.3390/vaccines9050410.
25. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA: A Cancer Journal for Clinicians, 2018;68: 394-424. https://doi.org/10.3322/caac.21492
26. American Association for Cancer Research (AACR). The Past, Present, and Future of HPV: Can Vaccination Help Eliminate Cervical Cancer? AACR Blog [Internet]. 2021 Sep 28. Available from:

27. Dursun P, Ayhan A, Mutlu L, et al. HPV types in Turkey: multicenter hospital based evaluation of 6388 patients in Turkish gynecologic oncology group centers. Turk Patoloji Derg.
2013;29(3):210-216. doi:10.5146/tjpath.2013.01188
28. Gultekin M, Dundar S, Keskinkilic B, et al. How to triage HPV positive cases: Results of four million females. Gynecol Oncol. 2020;158(1):105-111. doi:10.1016/j.ygyno.2020.04.698
29. Bansal A, Singh MP, Rai B. Human papillomavirus-associated cancers: A growing global problem. Int J Appl Basic Med Res. 2016;6(2):84-89. doi:10.4103/2229-516X.179027
30. Evande R, Rana A, Biswas-Fiss EE, Biswas SB. Protein–DNA Interactions Regulate Human Papillomavirus DNA Replication, Transcription, and Oncogenesis. Int. J. Mol. Sci. 2023, 24, 8493.
https://doi.org/10.3390/ ijms24108493
31. Williams J, Kostiuk M and Biron VL (2022) Molecular Detection Methods in HPV-Related Cancers. Front. Oncol. 12:864820. doi: 10.3389/fonc.2022.864820
32. Sindhuja T, Bhari N, Gupta S. Asian guidelines for condyloma acuminatum Infect Chemother. 2022 Jul;28(7):845-852. doi: 10.1016/j.jiac.2022.03.004.
33. Betz SJ. HPV-Related Papillary Lesions of the Oral Mucosa: A Review. Head Neck Pathol. 2019 Mar;13(1):80-90. doi: 10.1007/s12105-019-01003-7.
34. Rosalik K, Tarney C. Han J. Human Papilloma Virus Vaccination. Viruses 2021, 13, 1091. https://doi.org/10.3390/v13061091
35. Graham S.V. The Human Papillomavirus Replication Cycle, and Its Links to Cancer Progression: A Comprehensive Review. Clin. Sci. 2017;131:2201–2221. doi: 10.1042/CS20160786.
36. Meites E, Gee J, Unger E, Markowitz L. (2007). Human Papillomaviruses.
37. Gautam A, Gedda MR, Rai M, Sundar S, Chakravarty J. Human Papillomavirus Genome based Detection and Typing: A Holistic Molecular Approach. Curr Mol Med. 2019;19(4):237-246.
doi: 10.2174/1566524019666190405120441.
38. Wang YF. Signal Amplification Techniques: bDNA, Hybrid Capture. In: Tang YW, Stratton CW, editors. Advanced Techniques in Diagnostic Microbiology. USA: Springer; 2006:228-42.
39. Arbyn M, Simon M, Peeters E, et al. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect. 2021;27(8):1083-1095. doi:10.1016/j.
cmi.2021.04.031
40. Burd EM, Dean CL. Human Papillomavirus. Microbiol Spectr. 2016 Aug;4(4). doi: 10.1128/microbiolspec.DMIH2-0001-2015.
41. Soheili M, Keyvani H, Soheili M, Nasseri S. Human papilloma virus: A review study of epidemiology, carcinogenesis, diagnostic methods, and treatment of all HPV-related cancers. Med J
Islam Repub Iran. 2021; 22;35:65. doi: 10.47176/mjiri.35.65.
42. Singini MG, Singh E, Bradshaw D, et al. Usefulness of high-risk HPV early oncoprotein (E6 and E7) serological markers in the detection of cervical cancer: A systematic review and meta-a-
nalysis. J Med Virol. 2023;95(1):e27900. doi:10.1002/jmv.27900
43. Araújo MG, Magalhães GM, Garcia LC, Vieira ÉC, Carvalho-Leite MLR, Guedes ACM. Update on human papillomavirus – Part II: complementary diagnosis, treatment and prophylaxis. An
Bras Dermatol. 2021 Mar-Apr;96(2):125-138. doi: 10.1016/j.abd.2020.11.005.
44. Garbuglia AR, Lapa D, Sias C, Capobianchi MR and Del Porto P. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease. Front. Immunol.
2020;11:188. doi: 10.3389/fimmu.2020.00188
45. Centers for Disease Control and Prevention (CDC). Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on
Immunization Practices. MMWR Morb Mortal Wkly Rep. 2015; 64(11):300–304. Available from: https://www.cdc.gov/mmwr/pdf/wk/mm6411.pdf#page=12
46. National Cancer Institute. HPV and Cancer. National Cancer Institute [Internet]. 2024. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-
and-cancer
47. Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of Human Papillomavirus Vaccines: An Updated Review. Drug Saf. 2018;41(4):329-346. doi:10.1007/s40264-017-0625-z
48. Romanowski B, Naud PS, Roteli-Martins CM, De NSC, Teixeira JC, Aoki F, et al. Sustained Efficacy and Immunogenicity of the Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vac-
cine: Analysis of a Randomised Placebo- Controlled Trial Up to 6.4 Years. Lancet (London England) 2009; 374 (9706):1975–85. doi: 10.1016/S0140-6736(09)61567-1
49. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on
Immunization Practices. MMWR Morb Mortal Wkly Rep 2019;68:698–702. DOI: http://dx.doi.org/10.15585/mmwr.mm6832a3
50. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020: 70: 321-
346. https://doi.org/10.3322/caac.21628)
51. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors [published corre-
ction appears in J Low Genit Tract Dis. 2020 Oct;24(4):427]. J Low Genit Tract Dis. 2020;24(2):102-131. doi:10.1097/LGT.0000000000000525